Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011532 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Paule Hermet und 29 weiteren Autor:innen. Beteiligte Einrichtung: Icosagen Cell Factory OÜ; Tartu, Estonia. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Ettevõtluse Arendamise Sihtasutus, Eesti Teadusagentuur.
Abstract (Originalsprache)
The COVID-19 pandemic represents a global challenge that has impacted and is expected to continue to impact the lives and health of people across the world for the foreseeable future. The rollout of vaccines has provided highly anticipated relief, but effective therapeutics are required to further reduce the risk and severity of infections. Monoclonal antibodies have been shown to be effective as therapeutics for SARS-CoV-2, but as new variants of concern (VoC) continue to emerge, their utility and use have waned due to limited or no efficacy against these variants. Furthermore, cumbersome systemic administration limits easy and broad access to such drugs. As well, concentrations of systemically administered antibodies in the mucosal epithelium, a primary site of initial infection, are dependent on neonatal Fc receptor mediated transport and require high drug concentrations. To reduce the viral load more effectively in the lung, we developed an inhalable formulation of a SARS-CoV-2 neutralizing antibody binding to a conserved epitope on the Spike protein, ensuring pan-neutralizing properties. Administration of this antibody via a vibrating mesh nebulization device retained antibody integrity and resulted in effective distribution of the antibody in the upper and lower respiratory tract of non-human primates (NHP). In comparison with intravenous administration, significantly higher antibody concentrations can be obtained in the lung, resulting in highly effective reduction in viral load post SARS-CoV-2 challenge. This approach may reduce the barriers of access and uptake of antibody therapeutics in real-world clinical settings and provide a more effective blueprint for targeting existing and potentially emerging respiratory tract viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Icosagen Cell Factory OÜ; Tartu, Estonia.
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT); Fontenay-aux-Roses, France.
- York University; Toronto, Canada.
- University of Tartu; Tartu, Estonia.
- NTNU; Trondheim, Norway.
- Department of Biochemistry, University of Toronto; Toronto, Canada.
ORCID-Profile: Paule Hermet, Mart Ustav
Förderung
- CIHR
- Ettevõtluse Arendamise Sihtasutus
- Eesti Teadusagentuur
- Agence Nationale de la Recherche
- ANRS-MIE
- Natural Sciences and Engineering Research Council of Canada
- Canada Excellence Research Chairs, Government of Canada
- Canadian Institutes of Health Research
Zitieren
APA
Hermet, P., Delache, B., Herate, C., Wolf, E., Kivi, G., Juronen, E., Mumm, K., Žusinaite, E., Kainov, D., Sankovski, E., Virumäe, K., Planken, A., Merits, A., Besaw, J. E., Yee, A. W., Morizumi, T., Kim, K., Kuo, A., Berriche, A., …, & Ustav, M. (2023). Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011532
Vancouver
Hermet P, Delache B, Herate C, Wolf E, Kivi G, Juronen E, et al. Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011532
BibTeX
@article{Hermet2023,
author = {Hermet, Paule and Delache, Benoît and Herate, Cecile and Wolf, Esther and Kivi, Gaily and Juronen, Erkki and Mumm, Karl and Žusinaite, Eva and Kainov, Denis and Sankovski, Eve and Virumäe, Kai and Planken, Anu and Merits, Andres and Besaw, Jessica E and Yee, Ai Woon and Morizumi, Takefumi and Kim, Kyumhyuk and Kuo, Anling and Berriche, Asma and Dereuddre-Bosquet, Nathalie and Sconosciuti, Quentin and Naninck, Thibaut and Relouzat, Francis and Cavarelli, Mariangela and Ustav, Mart and Wilson, Derek and Ernst, Oliver P and Männik, Andres and LeGrand, Roger and Ustav, Mart},
title = {Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011532}
}
EUVIMED